Nephrocare Health Services Limited IPO Review
Neutral438-460 · Mainboard
✦
Analyst Verdict
Nephrocare Health Services Limited IPO
Neutral
IPO at a Glance
Price Band
438-460
Issue Size
871cr
Min. Investment
₹14,720
Opens
2025-12-08
Closes
2025-12-10
Listing
2025-12-15
Category
Mainboard
Key Strengths
✓Asia’s largest dialysis provider by treatment volumes.
✓447 centres ensuring broad national geographic reach.
✓Innovative models like holiday and mobile dialysis.
✓Strong patient base of over 33,000 annually.
✓Experienced management backed by private equity funding.
Key Risks
⚠Capital-intensive model requiring continuous funding support.
⚠Quality control challenges across a large clinic network.
⚠Dependent on kidney disease prevalence and policy support.
⚠Increasing competition from hospitals and local players.
⚠High operating costs may pressure profitability margins.
Frequently Asked Questions
Should I apply for Nephrocare Health Services Limited IPO?
Based on our analysis, our rating for Nephrocare Health Services Limited IPO is: Neutral. Review the full analysis including strengths, risks, and financials on CheckIPO before making a decision.
What are the key risks of Nephrocare Health Services Limited IPO?
Capital-intensive model requiring continuous funding support. Quality control challenges across a large clinic network. Dependent on kidney disease prevalence and policy support.
What are the strengths of Nephrocare Health Services Limited IPO?
Asia’s largest dialysis provider by treatment volumes. 447 centres ensuring broad national geographic reach. Innovative models like holiday and mobile dialysis.
What is the price band of Nephrocare Health Services Limited IPO?
The price band for Nephrocare Health Services Limited IPO is 438-460. The IPO has closed.
Full Analysis Available
Financials, DRHP breakdown, peer comparison, shareholding pattern & more